Oculis Holding AG (OCS) Other Operating Expenses (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Other Operating Expenses of -$0.0 for Q1 2026, down 100.1% quarter-over-quarter from $0.0 in Q3 2025.

Oculis Holding AG (OCS) Other Operating Expenses (2022 - 2026) Analysis & Trends

Oculis Holding AG's Other Operating Expenses history runs 5 years deep, the most recent figure standing at -$0.0 for Q1 2026.

In Q1 2026, Other Operating Expenses changed N/A year-over-year to -$0.0; the TTM figure through Mar 2026 stood at $0.0 (up 51100.0% YoY), while the FY2024 annual figure was $0.0, up 100.0% from the prior year.
Other Operating Expenses for Q1 2026 stood at -$0.0, down from $0.0 in the prior quarter.
The five-year high for Other Operating Expenses was $2.7 million in Q2 2023, with the low at -$35.4 million in Q1 2023.
The 5-year median for Other Operating Expenses is $0.0 (2022), against an average of -$4.1 million.
The sharpest annual moves came in 2023 and 2024: Other Operating Expenses soared 7658529219999900.0% in 2023, then sank 100.0% in 2024.
Oculis Holding AG's Other Operating Expenses stood at -$0.0 in 2022, then jumped by 3829264610000000.0% to $71325.6 in 2023, then slumped by 100.0% to $0.0 in 2024, then surged by 102300.0% to $0.0 in 2025, then sank by 100.1% to -$0.0 in 2026.
Business Quant data shows OCS's Other Operating Expenses at -$0.0 in Q1 2026, $0.0 in Q3 2025, and $0.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Oculis Holding AG	879.09 Mn	590.21 Mn	-

Download Data